[Form 4] Editas Medicine, Inc. Insider Trading Activity
Editas Medicine insider transaction by SVP & Chief Financial Officer Amy Parison: The filing reports a non-discretionary sale of 679 shares of common stock at $2.58 per share, executed under a durable automatic sales instruction plan. The sale satisfied tax withholding obligations arising from the vesting of restricted stock units and is explicitly described as not a discretionary trade by the reporting person.
After the reported sale the reporting person beneficially owned 16,827 shares directly. The filing identifies the issuer as Editas Medicine, Inc. and classifies the report as a Form 4 statement of changes in beneficial ownership.
Operazione di insider di Editas Medicine da parte della SVP e Chief Financial Officer Amy Parison: La comunicazione riporta una vendita non discrezionale di 679 azioni ordinarie a $2,58 per azione, eseguita nell'ambito di un piano permanente di istruzioni automatiche di vendita. La vendita ha soddisfatto gli obblighi di ritenuta fiscale derivanti dal vesting di unit脿 azionarie vincolate (RSU) ed 猫 esplicitamente indicata come non discrezionale da parte della persona che effettua la segnalazione.
Dopo la vendita segnalata la persona beneficiaria deteneva direttamente 16,827 azioni. La comunicazione identifica l'emittente come Editas Medicine, Inc. e classifica il rapporto come un Form 4, dichiarazione di variazione della propriet脿 beneficiaria.
Operaci贸n de informaci贸n privilegiada de Editas Medicine por la SVP y Chief Financial Officer Amy Parison: La presentaci贸n informa de una venta no discrecional de 679 acciones ordinarias a $2.58 por acci贸n, ejecutada bajo un plan permanente de instrucciones autom谩ticas de venta. La venta cumpli贸 con las obligaciones de retenci贸n fiscal derivadas del vesting de unidades restringidas de acciones (RSU) y se describe expl铆citamente como no una operaci贸n discrecional por parte de la persona que informa.
Despu茅s de la venta informada, la persona informante pose铆a directamente 16,827 acciones. La presentaci贸n identifica al emisor como Editas Medicine, Inc. y clasifica el informe como un Formulario 4, declaraci贸n de cambios en la propiedad beneficiaria.
Editas Medicine 雮措秬鞛� 瓯半灅 鈥� SVP 瓴� 斓滉碃鞛毂呾瀯鞛� Amy Parison: 鞝滌稖靹滊電� 歆�靻嶌爜鞚� 鞛愲彊 毵る弰 歆�鞁� 瓿勴殟鞐� 霐半澕 鞁ろ枆霅� 679欤�鞚� 牍勳灛霟夓爜 氤错喌欤� 毵り皝鞚� 氤搓碃頃╇媹雼�. 毵る弰 雼皜電� $2.58鞛呺媹雼�. 鞚� 毵り皝鞚� 鞝滍暅欤检嫕雼渼(RSU)鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頄堨溂氅�, 鞁犼碃鞚胳潃 鞚措ゼ 氇呾嫓鞝侅溂搿� 鞛焿鞝� 瓯半灅臧� 鞎勲媹霛缄碃 靹る獏頃橁碃 鞛堨姷雼堧嫟.
氤搓碃霅� 毵り皝 鞚错泟 鞁犼碃鞚胳潃 歆侅爲鞝侅溂搿� 16,827欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖靹滊電� 氚滍枆須岇偓毳� Editas Medicine, Inc.搿� 頇曥澑頃橁碃 頃措嫻 氤搓碃靹滊ゼ 靻岇湢甓� 氤�霃� 鞁犼碃靹滌澑 Form 4搿� 攵勲頃╇媹雼�.
Transaction d'initi茅 d'Editas Medicine par la SVP et Directrice Financi猫re Amy Parison : Le d茅p么t indique une vente non discr茅tionnaire de 679 actions ordinaires 脿 2,58 $ par action, ex茅cut茅e dans le cadre d'un plan p茅renne d'instructions automatiques de vente. La vente a satisfait les obligations de retenue fiscale d茅coulant du vesting d'unit茅s d'actions restreintes (RSU) et est explicitement d茅crite comme n'茅tant pas une op茅ration discr茅tionnaire de la personne d茅clarante.
Apr猫s la vente signal茅e, la personne d茅clarante d茅tenait directement 16,827 actions. Le d茅p么t identifie l'茅metteur comme Editas Medicine, Inc. et classe le rapport comme un Formulaire 4, d茅claration de changements dans la propri茅t茅 b茅n茅ficiaire.
Insider-Transaktion von Editas Medicine durch SVP & Chief Financial Officer Amy Parison: Die Einreichung meldet einen nicht-diskretion盲ren Verkauf von 679 Stammaktien zu $2,58 pro Aktie, ausgef眉hrt im Rahmen eines dauerhaften automatischen Verkaufsinstruktionsplans. Der Verkauf erf眉llte Steuerabzugsverpflichtungen, die aus dem Vesting von Restricted Stock Units (RSU) resultieren, und wird ausdr眉cklich nicht als diskretion盲rer Handel der meldenden Person bezeichnet.
Nach dem gemeldeten Verkauf besa脽 die meldende Person direkt 16,827 Aktien. Die Einreichung identifiziert den Emittenten als Editas Medicine, Inc. und klassifiziert den Bericht als Form 4, Erkl盲rung 眉ber 脛nderungen im wirtschaftlichen Eigentum.
- Sale executed under a pre-established automatic sales instruction plan, indicating it was not a discretionary trade
- Transaction purpose explicitly disclosed as covering tax withholding from RSU vesting
- Post-transaction beneficial ownership disclosed (16,827 shares), improving transparency
- Reduction in direct holdings of 679 shares following the sale
- Sale price reported at $2.58 per share, reflecting the price realized on the disposition
Insights
TL;DR: Routine, non-discretionary sale to cover taxes; small, likely immaterial change to holdings.
The transaction is clearly documented as a sale under an automatic instruction plan to cover tax withholding from RSU vesting. The economics are transparent: 679 shares sold at $2.58 each. This type of sale typically signals no active trading decision by the officer and therefore lacks fresh informational content about company prospects. From a market-impact standpoint, the size of the sale is small relative to typical public float and is unlikely to affect valuation.
TL;DR: Proper use of pre-established plan and explicit disclosure reduces governance concerns.
The reporting person discloses that the sale was effected pursuant to a durable automatic sales instruction plan adopted in 2022 and was executed to satisfy tax withholding on vested RSUs. Stating that the sale was not discretionary and providing the plan context adheres to best practices for insider transaction transparency. The Form 4 presentation is complete for the reported non-derivative transaction and includes post-transaction beneficial ownership.
Operazione di insider di Editas Medicine da parte della SVP e Chief Financial Officer Amy Parison: La comunicazione riporta una vendita non discrezionale di 679 azioni ordinarie a $2,58 per azione, eseguita nell'ambito di un piano permanente di istruzioni automatiche di vendita. La vendita ha soddisfatto gli obblighi di ritenuta fiscale derivanti dal vesting di unit脿 azionarie vincolate (RSU) ed 猫 esplicitamente indicata come non discrezionale da parte della persona che effettua la segnalazione.
Dopo la vendita segnalata la persona beneficiaria deteneva direttamente 16,827 azioni. La comunicazione identifica l'emittente come Editas Medicine, Inc. e classifica il rapporto come un Form 4, dichiarazione di variazione della propriet脿 beneficiaria.
Operaci贸n de informaci贸n privilegiada de Editas Medicine por la SVP y Chief Financial Officer Amy Parison: La presentaci贸n informa de una venta no discrecional de 679 acciones ordinarias a $2.58 por acci贸n, ejecutada bajo un plan permanente de instrucciones autom谩ticas de venta. La venta cumpli贸 con las obligaciones de retenci贸n fiscal derivadas del vesting de unidades restringidas de acciones (RSU) y se describe expl铆citamente como no una operaci贸n discrecional por parte de la persona que informa.
Despu茅s de la venta informada, la persona informante pose铆a directamente 16,827 acciones. La presentaci贸n identifica al emisor como Editas Medicine, Inc. y clasifica el informe como un Formulario 4, declaraci贸n de cambios en la propiedad beneficiaria.
Editas Medicine 雮措秬鞛� 瓯半灅 鈥� SVP 瓴� 斓滉碃鞛毂呾瀯鞛� Amy Parison: 鞝滌稖靹滊電� 歆�靻嶌爜鞚� 鞛愲彊 毵る弰 歆�鞁� 瓿勴殟鞐� 霐半澕 鞁ろ枆霅� 679欤�鞚� 牍勳灛霟夓爜 氤错喌欤� 毵り皝鞚� 氤搓碃頃╇媹雼�. 毵る弰 雼皜電� $2.58鞛呺媹雼�. 鞚� 毵り皝鞚� 鞝滍暅欤检嫕雼渼(RSU)鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頄堨溂氅�, 鞁犼碃鞚胳潃 鞚措ゼ 氇呾嫓鞝侅溂搿� 鞛焿鞝� 瓯半灅臧� 鞎勲媹霛缄碃 靹る獏頃橁碃 鞛堨姷雼堧嫟.
氤搓碃霅� 毵り皝 鞚错泟 鞁犼碃鞚胳潃 歆侅爲鞝侅溂搿� 16,827欤�毳� 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞝滌稖靹滊電� 氚滍枆須岇偓毳� Editas Medicine, Inc.搿� 頇曥澑頃橁碃 頃措嫻 氤搓碃靹滊ゼ 靻岇湢甓� 氤�霃� 鞁犼碃靹滌澑 Form 4搿� 攵勲頃╇媹雼�.
Transaction d'initi茅 d'Editas Medicine par la SVP et Directrice Financi猫re Amy Parison : Le d茅p么t indique une vente non discr茅tionnaire de 679 actions ordinaires 脿 2,58 $ par action, ex茅cut茅e dans le cadre d'un plan p茅renne d'instructions automatiques de vente. La vente a satisfait les obligations de retenue fiscale d茅coulant du vesting d'unit茅s d'actions restreintes (RSU) et est explicitement d茅crite comme n'茅tant pas une op茅ration discr茅tionnaire de la personne d茅clarante.
Apr猫s la vente signal茅e, la personne d茅clarante d茅tenait directement 16,827 actions. Le d茅p么t identifie l'茅metteur comme Editas Medicine, Inc. et classe le rapport comme un Formulaire 4, d茅claration de changements dans la propri茅t茅 b茅n茅ficiaire.
Insider-Transaktion von Editas Medicine durch SVP & Chief Financial Officer Amy Parison: Die Einreichung meldet einen nicht-diskretion盲ren Verkauf von 679 Stammaktien zu $2,58 pro Aktie, ausgef眉hrt im Rahmen eines dauerhaften automatischen Verkaufsinstruktionsplans. Der Verkauf erf眉llte Steuerabzugsverpflichtungen, die aus dem Vesting von Restricted Stock Units (RSU) resultieren, und wird ausdr眉cklich nicht als diskretion盲rer Handel der meldenden Person bezeichnet.
Nach dem gemeldeten Verkauf besa脽 die meldende Person direkt 16,827 Aktien. Die Einreichung identifiziert den Emittenten als Editas Medicine, Inc. und klassifiziert den Bericht als Form 4, Erkl盲rung 眉ber 脛nderungen im wirtschaftlichen Eigentum.
FAQ
What insider transaction did Editas (EDIT) report for Amy Parison?
Why were the 679 shares sold according to the filing?
Was the sale a discretionary trade or part of a plan?
At what price were the shares sold and what are holdings after the sale?
Does the Form 4 indicate any derivative transactions by the reporting person?
